EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Epidemiology and outcomes of alpha‐1 antitrypsin deficiency in Sweden 2002–2020: A population‐based cohort study of 2286 individuals

Staffan Wahlin iD, Linnea Widman, Hannes Hagström iD

Journal of Internal Medicine · 2025

DOI: 10.1111/joim.20058 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Internal Medicine, 2025. Verfasst von Staffan Wahlin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin Deficiency. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To estimate the incidence, prevalence, and outcomes of patients with diagnosed alpha‐1‐antitrypsin deficiency (AATD) in Sweden, 2002–2020. Study design and setting The Swedish National Patient Registry was utilized to identify patients with a first diagnosis of AATD between 2002 and 2020. Each patient was matched with up to 10 comparators from the general population. AATD incidence and prevalence were estimated. Causes of death and rates of mortality, transplantation, lung disease, liver cirrhosis, and previous neonatal cholestasis were estimated.

Results

The incidence rate of AATD was 1.83 (95% confidence interval [CI] 1.58–2.11) per 100,000 person‐years and the total prevalence was 21.04 (95%CI = 20.17–21.94) per 100,000 persons at the end of 2020. Mortality was 3.55 times higher (95%CI = 3.15–3.99) for patients with AATD. Rates of liver—(hazard ratio [HR] = 22.95, 95%CI = 12.61–41.75), lung—(HR = 12.09, 95%CI = 8.87–16.47), and cardiovascular (HR = 1.90, 95%CI = 1.45–2.90) related death were higher in patients with AATD. The cumulative incidence after 10 years of follow‐up was 1.69% (95%CI = 1.15–2.41) for liver transplantation and 4.14% (95%CI = 3.20–5.26) for lung transplantation. About 20% of patients were estimated to be alive without lung disease or liver cirrhosis 20 years after an AATD diagnosis. Neonatal cholestasis codes were found in 3.0% of AATD patients and 0.5% of comparators (odds ratio 6.28, 95%CI = 3.81–10.36).

Conclusions

In this population‐based cohort study on AATD in Sweden, an increasing incidence was observed, and significantly higher rates of death from liver, lung, and cardiovascular causes compared to the general population were found. Only a minority of diagnosed AATD patients were estimated to be free of liver cirrhosis and lung disease after 20 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha 1-Antitrypsin DeficiencyHumansSwedenMaleFemaleIncidenceMiddle AgedAdultPrevalenceRegistriesCohort StudiesAgedYoung AdultCause of DeathAdolescentLiver CirrhosisInfantChild

Stichwörter der Autor:innen

incidenceliver cirrhosisliver transplantationlung transplantationmortalityprevalence

Autor:innen und Institutionen

  • Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Division of Hepatology, Department of Upper GI Diseases, Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Staffan Wahlin, Hannes Hagström

Zitieren

APA

Wahlin, S., Widman, L., & Hagström, H. (2025). Epidemiology and outcomes of alpha‐1 antitrypsin deficiency in Sweden 2002–2020: A population‐based cohort study of 2286 individuals. Journal of Internal Medicine. https://doi.org/10.1111/joim.20058

Vancouver

Wahlin S, Widman L, Hagström H. Epidemiology and outcomes of alpha‐1 antitrypsin deficiency in Sweden 2002–2020: A population‐based cohort study of 2286 individuals. Journal of Internal Medicine. 2025. doi:10.1111/joim.20058

BibTeX
@article{Wahlin2025,
  author = {Wahlin, Staffan and Widman, Linnea and Hagström, Hannes},
  title = {Epidemiology and outcomes of alpha‐1 antitrypsin deficiency in Sweden 2002–2020: A population‐based cohort study of 2286 individuals},
  journal = {Journal of Internal Medicine},
  year = {2025},
  doi = {10.1111/joim.20058}
}
Kostenlos starten →